



**SYNTHESIS OF N-METHYLATED ANALOG OF AMIDOMYCIN:
A POTENT ANTIMICROBIAL CYCLOHEPTAPEPTIDE**

Himaja M.^{1*}, Ogale Sachin Ramachandra Rao², Moonjit Das¹ and Asif Karigar³

¹Pharmaceutical Chemistry Division, School of Advanced Sciences, VIT University, Vellore, Tamil Nadu, India

²Department of Pharmaceutical Chemistry, Nitte Gulabi Shetty Memorial Institute of Pharmaceutical Sciences, Nanthoor, Mangalore, India

³Department of Pharmaceutical Analysis, Maratha Mandal's College of Pharmacy, Belgaum, Karnataka, India

*Corresponding Author Email: drmhimaja@gmail.com

DOI: 10.7897/2277-4572.033142

Published by Moksha Publishing House. Website www.mokshaph.com

All rights reserved.

Received on: 05/04/14 Revised on: 02/05/14 Accepted on: 05/06/14

ABSTRACT

N-methylated analog of Amidomycin, was synthesized by solution phase peptide synthesis using dicyclohexylcarbodiimide (DCC) as the coupling agent and triethylamine (TEA) as the base. The structure of the compound was confirmed by IR, ¹H NMR, ¹³C NMR, FABMASS and elemental analysis. The synthesized cyclic peptide was evaluated for Minimum Inhibitory Concentration (MIC) against four strains of bacteria and three strains of fungi. It was found to be active against both bacteria and fungi from 50-100 µg.

Keywords: Amidomycin, solution phase peptide synthesis, DCC, MIC.

INTRODUCTION

Amidomycin, a cyclic depsipeptide, was produced by a *Streptomyces* species. In the year 1957, Vining L.C. *et al.*¹ first isolated it and elucidated its structure. Synthesis of amidomycin was carried out by Shemyakin M. M. *et al.* in the year 1963². It is an antibiotic which is primarily active against yeasts. However, no further studies were carried out on Amidomycin because of the complexity of the synthesis of the alternate amide and ester linkages and usage of D-amino acid which is very costly. Hence simple analogues were designed with only amide linkages, thus making synthesis easier and cost effective by incorporating L-amino acids. N-methylated amino acids are commonly found in naturally occurring peptide antibiotics. The methylation of N-atom eliminates the hydrogen, responsible for cleavage of peptide bonds. The hydrogen bonding pattern of peptide containing these amino acids is different from that of unmethylated forms.³⁻⁵ N-methylated cyclic peptides is found to possess cytotoxic and antimicrobial activity. A review of the structures of cyclic peptides exhibiting antimicrobial activity showed presence of at least one D-amino acid and/or N-methylated amino acid units in the molecule. Hence the cyclic octapeptide analogue of amidomycin have been designed containing one N-methyl-L-valine and rest L-valine units. In order to carry out the synthesis, the cyclic octapeptide was disconnected into four dipeptide units. The dipeptides were prepared from the respective protected amino acids. The amino group was protected with tertiary Butyloxycarbonyl (Boc-) group and the carboxyl group was protected by converting it into the methyl ester. The Boc-amino acids were coupled with the amino acid methyl ester hydrochlorides by dicyclohexylcarbodiimide (DCC) as the coupling agent and triethylamine (TEA) as the base to get the protected dipeptides. The dipeptides were appropriately deprotected and coupled to get the octapeptides, which were finally cyclised by p-nitrophenyl ester method using high-dilution technique to get the cyclic octapeptide.

MATERIALS AND METHODS

All the reactions requiring anhydrous conditions were conducted in dried apparatus. All the reactions were magnetically stirred unless otherwise stated. Organic extracts were dried over anhydrous sodium sulphate. Melting points were determined by capillary method and were uncorrected. Amino acids, di-tert-butylpyrocarbonate, trifluoroacetic acid and triethylamine were obtained from Spectrochem Ltd. Mumbai, India. DCC, Diethyl ether, Methanol and Chloroform was obtained from AVRA. IR spectra were recorded on Jasco FT/IR-5300 IR spectrometer using a thin film supported on KBr pellets for solids and chloroform as a solvent for semisolids. The values are reported as ν_{\max} (cm⁻¹). ¹H NMR spectra were recorded on Bruker JOEL (400 MHz) NMR spectrometer. The spectra were obtained in CDCl₃ and the chemical shift values are reported as values in ppm relative to TMS ($\delta = 0$) as internal standard. FABMASS spectra were recorded on a Joel Sx 102/DA-6000 mass spectrometer using xenon as the carrier gas. The spectra were recorded at room temperature; m-nitrobenzyl alcohol was used as the matrix. The protection of amino and carboxyl group and their de protection were done by standard procedures.⁶⁻⁹

N-methylation of Boc-amino acid

Boc-amino acid (0.663 g, 2.0 mmol) was dissolved in dry THF (20 ml) and cooled to 0°C. To this NaH (2.88 g, 12 mmol) and MeI (0.852 g, 6.0 mmol) were added and stirred overnight at room temperature. The reaction mixture was diluted with ether (20 ml), washed with sat. NH₄Cl (10 ml), 20 % Na₂S₂O₃ solution and sat. NaCl solution (10 ml); Organic layer was dried and concentrated. Using the above method following N-methyl amino acid was prepared.

Preparation of Dipeptides

Amino acid methyl ester hydrochloride (10 mmol) was dissolved in chloroform (CHCl₃) (20 ml). To this, TEA (4 ml, 28.7 mmol) was added at 0°C and the reaction mixture was stirred for 15 minutes. Boc-amino acid (10 mmol) in CHCl₃

(20 ml) and DCC (10 mmol) were added with stirring. After 36 h, the reaction mixture was filtered and the residue was washed with CHCl_3 (30 ml) and added to the filtrate. The filtrate was washed with 5 % NaHCO_3 (20 ml), 5 % HCl (20 ml) and distilled H_2O (20 ml). The organic layer was dried over anhydrous Na_2SO_4 , filtered and evaporated in a vacuum. The residue was purified by re crystallization from CHCl_3 . Boc-L-Val-Val-OMe and Boc-N-methyl-L-Val-L-Val-OMe was prepared in this manner.

Preparation of Tetrapeptides

The de protected dipeptide units were coupled using DCC/TEA to get the protected tetrapeptide by the procedure similar to that of the dipeptides. Boc-L-[Val-Val-Val-Val]-OMe and Boc-N-methyl-L-Val-L-[Val-Val-Val]-OMe were synthesized in this manner.


Preparation of linear octapeptide

The Boc-group of the tetrapeptides Boc-L-[Val-Val-Val-Val]-OMe was removed and the ester group of the

tetrapeptide Boc-L-Val-L-Val-N-methyl-L-Val-L-Val-OMe was de protected. Both the de protected units were coupled to get the linear octapeptide.

Preparation of Cyclic octapeptide

The cyclisation of the linear octapeptide unit was carried out by the p-nitrophenyl ester⁶ with certain modifications. The ester group of the linear fragment was removed and the p-nitrophenyl ester group was introduced by stirring it for 12 h in CHCl_3 with p-nitrophenol at 0°C . The reaction mixture was washed several times with saturated NaHCO_3 until the unreacted p-nitrophenol was removed completely and washed with 5 % HCl to get Boc-peptide-pnp ester. The Boc-group was also removed, CHCl_3 and pyridine was added and the reaction mixture was kept at 0°C for 10 days. The mixture was finally washed with 5 % HCl , dried and evaporated in vacuum to get the cyclised product, which was then re crystallized from $\text{CHCl}_3/\text{n-hexane}$ (Scheme 1).



Scheme 1

Determination of Minimum Inhibitory Concentration (MIC)

The MIC of the cyclic peptide was determined by the serial tube dilution technique¹⁰⁻¹² against two strains of Gram positive bacteria (*Staphylococcus aureus* and *Bacillus subtilis*), two strains of Gram negative bacteria (*Escherichia coli* and *Pseudomonas aeruginosa*) and three strains of fungi (*Candida albicans*, *Aspergillus flavus* and *Aspergillus fumigatus*). 4 mg of the sample was dissolved in 2 ml of sterile dimethyl formamide (DMF) to obtain stock solution having concentration of 200 µg/ml. In serial dilution technique, 1 ml prepared stock solution was transferred to test tube containing 1 ml nutrient broth medium for bacterial cultures and 1 ml Potato Dextrose Broth (PDB) for fungal

cultures to give concentration 100 µg/ml from which 1 ml was transferred to another test tube containing 1 ml of broth medium to give concentration 50 µg/ml and so on up to concentration 6.25 µg/ml. After preparation of suspension of test organisms (10 organisms per ml), 1 drop of suspension (0.02 ml) was added to each broth dilution; a positive control was prepared in a similar way except that the test compound was not added. A negative control was prepared without the test compound and the test organisms. Tubes inoculated with bacterial cultures were incubated aerobically at 37°C for 24 hours and tubes inoculated with fungal cultures were incubated aerobically at 25°C for 48 hours. The tubes were observed for the presence/absence of growth.

Concentration of the solutions of the Test Compound

Concentration of the stock solution = 4 mg/2 ml (200 µg/ml)						
Tube number	I	II	III	IV	V	VI
Concentration µg/ml	6.25	12.5	25	50	100	200

RESULTS AND DISCUSSION

Physical Data and Spectral Analysis

Cyclo-N-methyl-L-Val-L-[Val-Val-Val-Val-Val]

Yield 81.35 %; light brown semisolid; IR spectrum (ν/cm^{-1}): 3287.4 cm^{-1} (br. s, -NH Stretch), 2932 cm^{-1} (s, -CH stretch), 1647.3 cm^{-1} (s, C=O stretch), 1557 cm^{-1} (s, -NH bend), 1452.8 cm^{-1} (s, NH bend); ¹H NMR spectrum (δ , ppm): 8.05(1H, br. s, -NH), 7.4(3H, br. s, -NH), 6.9(1H, br.s, -NH), 6.45(3H, br. s, -NH), 4.6(2H, m, α -H), 4.4(1H, m, α -H), 4.25(2H, m, α -H), 4.1(2H, m, α -H), 4.0(1H, m, α -H), 2.2(3H, s, -NCH₃), 1.4-1.0(8H, m, β -H), 1.0-0.9(48H, m, -CH₃); ¹³C NMR: (75.467MHz, CDCl₃): 170.4(C=O of Val), 59.9(α -C), 52.7(α -C), 52.0 (α -C), 48.7(α -C), 33.8 (β -C),

33.5 (β -C), 32.8 (β -C), 32.2 (β -C), 31.0 (β -C), 30.5 (β -C), 30.2 (β -C), 29.6 (β -C), 25.9 (CH₃), 25.6 (CH₃), 25.4 (CH₃), 25.2 (CH₃), 24.9 (CH₃), 24.7 (CH₃), 19.2 (CH₃), 18.8 (CH₃), 17.8 (CH₃); FABMASS: m/z (M + 1)⁺ = 809; Elemental Analysis: M. F. = C₄₁H₇₄N₈O₈, M. W. = 809, Found (Cal) % C: 64.43 (65.13), % N: 9.97 (10.0).

Minimum Inhibitory Concentration (MIC)

The synthesized cyclic peptides were evaluated for antibacterial and antifungal activities (MIC) from 200 µg to 6.25 µg. The cyclic peptide showed activity from 50 µg to 200 µg against all bacterial and fungal strains. The results of the MIC are given in Table 1 and Table 2.

Table 1: Minimum Inhibitory Concentration for Antibacterial Activity

Comp. No.↓	Presence/absence of growth																							
	<i>S. aureus</i>						<i>B. subtilis</i>						<i>E. coli</i>						<i>P. aeruginosa</i>					
Organism →																								
Dilution →	I	II	III	IV	V	VI	I	II	III	IV	V	VI	I	II	III	IV	V	VI	I	II	III	IV	V	VI
CP-2	-	-	-	+	+	+	-	-	-	+	+	+	-	-	-	+	+	+	-	-	-	+	+	+

'+' indicates presence of growth, '-' indicates absence of growth

Table 2: Minimum inhibitory concentration for antifungal activity

Compd. No.↓	Presence/absence of growth																	
	<i>C. albicans</i>						<i>A. flavus</i>						<i>A. fumigatus</i>					
Organism →																		
Dilution →	I	II	III	IV	V	VI	I	II	III	IV	V	VI	I	II	III	IV	V	VI
CP-2	-	-	-	+	+	+	-	-	+	+	+	+	-	-	-	+	+	+

'+' indicates presence of growth, '-' indicates absence of growth

CONCLUSION

The N-methylated cyclic octapeptide could be conveniently and efficiently synthesized by the prescribed scheme with good yields. The structure of the cyclic peptide was confirmed by IR, ¹H NMR, ¹³C NMR, FABMASS and elemental analysis. The compounds were screened for the Minimum Inhibitory Concentration (MIC) against four strains of bacteria and three strains of fungi and it was found to be active against both bacteria and fungi from 50-200 µg.

ACKNOWLEDGEMENTS


We are grateful to the DST/VIT-SIF Lab, School of Advanced Sciences, VIT University, Vellore, India for the support of this research.

REFERENCES

- Vining LC, Taber WA. Amidomycin, a new antibiotic from a *Streptomyces* species Can J Chem 1957; 35: 1109. <http://dx.doi.org/10.1139/v57-151>
- Shemyakin MM, Vinogradova EI, Feigina MY, Aldanova NA. On the structure of amidomycin and valinomycin, Tetrahedron Letters 1963; 4(6): 351-356. [http://dx.doi.org/10.1016/S0040-4039\(01\)90635-5](http://dx.doi.org/10.1016/S0040-4039(01)90635-5)

- Belagali SL, Matthew T, Himaja M, Kocienski PA. A highly efficient method of N-methylation for the amino acid derivatives. *Indian J Org Chem* 1995; 34: 44.
- Himaja M, Vani G, Ramana MV, Karigar A, Munirajasekhar D. Synthesis of Glabrin A and its N-methylated analog as potent insecticidal agents. *Int. J. Res. Ayu. Pharm* 2012; 3(1): 91-94.
- Das P, Himaja M. Design and synthesis of 4-[2'-(5'- nitro)] imidazolyl benzoyl (n-methyl) amino acids and peptides. *Int J Drug Dev Res* 2010; 2(2): 364-370.
- Dahiya R, Gautam H. Total synthesis and antimicrobial activity of a natural cycloheptapeptide of marine origin. *Marine Drugs* 2010; 8: 2384. <http://dx.doi.org/10.3390/md8082384>
- Bodanszky M, Bodanszky A. *Practice of Peptide Synthesis*. Springer-Verlag, New York; 1984. p. 78. <http://dx.doi.org/10.1007/978-3-642-96835-8>
- Das M, Agarwal DS, Sharma SK, Das P, Rout PK. Synthesis, docking studies and free radical scavenging activity of the linear tetrapeptide VFPP. *Int. Res. J. Pharm* 2012; 3(6): 138.
- Das M, Himaja M. Synthesis, antioxidant and anthelmintic activity of the linear tetrapeptide L-(Leu-Pro-Gly)-D-Ala (LPGA). *Int. J. Pharm. Pharm. Sci* 2013; 5 (Suppl 3): 713.
- Ekramul IM, Ekramul HM, Ashiik MM. Cytotoxicity and antibacterial activity of *Sida rhombifolia* (Malvaceae) grown in Bangladesh. *Phyt Res* 2003; 17(8): 978-975.
- Marjorie CM. Plant products as antimicrobial agents. *Clin Microbiol Rev* 1999; 12(4): 564-582.
- Roy S, Choudhury MD, Paul SB. *In vitro* Antibacterial activity of *Alocasia decipiens* schott. *Int J Pharm Pharm Sci* 2013; 5 Suppl 1: 155-157.

Source of support: Nil, Conflict of interest: None Declared



How to cite this article:

Himaja M., Ogale Sachin Ramachandra Rao, Moonjit Das and Asif Karigar. Synthesis of N-methylated analog of amidomycin: A potent antimicrobial cycloheptapeptide. *J Pharm Sci Innov.* 2014;3(3):217-220 <http://dx.doi.org/10.7897/2277-4572.033142>